• XOMA reported net income of USD 4.5 million, while total income and revenues fell to USD 12.32 million.
• Income from purchased receivables under the EIR method rose to USD 9.24 million, while income under the cost recovery method dropped to USD 2.77 million.
• General and administrative expense climbed to USD 11.86 million, while research and development expense narrowed to USD 49,000.
• Cash and cash equivalents increased to USD 85.6 million, while net cash provided by operating activities rose to USD 6.12 million.
• Ligand agreed to acquire XOMA for USD 39.00 per share in cash, valuing equity at about USD 739 million; deal targeted to close in Q3 2026, with one CVR per share tied to 75% of any net proceeds from Janssen litigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059369), on May 12, 2026, and is solely responsible for the information contained therein.